Cargando…
Treatment of Pulmonary Disease of Cystic Fibrosis: A Comprehensive Review
Cystic fibrosis (CF) is a genetic disease that causes absence or dysfunction of a protein named transmembrane conductance regulatory protein (CFTR) that works as an anion channel. As a result, the secretions of the organs where CFTR is expressed are very viscous, so their functionality is altered. T...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8144952/ https://www.ncbi.nlm.nih.gov/pubmed/33922413 http://dx.doi.org/10.3390/antibiotics10050486 |
_version_ | 1783697066681171968 |
---|---|
author | Girón Moreno, Rosa María García-Clemente, Marta Diab-Cáceres, Layla Martínez-Vergara, Adrián Martínez-García, Miguel Ángel Gómez-Punter, Rosa Mar |
author_facet | Girón Moreno, Rosa María García-Clemente, Marta Diab-Cáceres, Layla Martínez-Vergara, Adrián Martínez-García, Miguel Ángel Gómez-Punter, Rosa Mar |
author_sort | Girón Moreno, Rosa María |
collection | PubMed |
description | Cystic fibrosis (CF) is a genetic disease that causes absence or dysfunction of a protein named transmembrane conductance regulatory protein (CFTR) that works as an anion channel. As a result, the secretions of the organs where CFTR is expressed are very viscous, so their functionality is altered. The main cause of morbidity is due to the involvement of the respiratory system as a result of recurrent respiratory infections by different pathogens. In recent decades, survival has been increasing, rising by around age 50. This is due to the monitoring of patients in multidisciplinary units, early diagnosis with neonatal screening, and advances in treatments. In this chapter, we will approach the different therapies used in CF for the treatment of symptoms, obstruction, inflammation, and infection. Moreover, we will discuss specific and personalized treatments to correct the defective gene and repair the altered protein CFTR. The obstacle for personalized CF treatment is to predict the drug response of patients due to genetic complexity and heterogeneity of uncommon mutations. |
format | Online Article Text |
id | pubmed-8144952 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-81449522021-05-26 Treatment of Pulmonary Disease of Cystic Fibrosis: A Comprehensive Review Girón Moreno, Rosa María García-Clemente, Marta Diab-Cáceres, Layla Martínez-Vergara, Adrián Martínez-García, Miguel Ángel Gómez-Punter, Rosa Mar Antibiotics (Basel) Review Cystic fibrosis (CF) is a genetic disease that causes absence or dysfunction of a protein named transmembrane conductance regulatory protein (CFTR) that works as an anion channel. As a result, the secretions of the organs where CFTR is expressed are very viscous, so their functionality is altered. The main cause of morbidity is due to the involvement of the respiratory system as a result of recurrent respiratory infections by different pathogens. In recent decades, survival has been increasing, rising by around age 50. This is due to the monitoring of patients in multidisciplinary units, early diagnosis with neonatal screening, and advances in treatments. In this chapter, we will approach the different therapies used in CF for the treatment of symptoms, obstruction, inflammation, and infection. Moreover, we will discuss specific and personalized treatments to correct the defective gene and repair the altered protein CFTR. The obstacle for personalized CF treatment is to predict the drug response of patients due to genetic complexity and heterogeneity of uncommon mutations. MDPI 2021-04-23 /pmc/articles/PMC8144952/ /pubmed/33922413 http://dx.doi.org/10.3390/antibiotics10050486 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Girón Moreno, Rosa María García-Clemente, Marta Diab-Cáceres, Layla Martínez-Vergara, Adrián Martínez-García, Miguel Ángel Gómez-Punter, Rosa Mar Treatment of Pulmonary Disease of Cystic Fibrosis: A Comprehensive Review |
title | Treatment of Pulmonary Disease of Cystic Fibrosis: A Comprehensive Review |
title_full | Treatment of Pulmonary Disease of Cystic Fibrosis: A Comprehensive Review |
title_fullStr | Treatment of Pulmonary Disease of Cystic Fibrosis: A Comprehensive Review |
title_full_unstemmed | Treatment of Pulmonary Disease of Cystic Fibrosis: A Comprehensive Review |
title_short | Treatment of Pulmonary Disease of Cystic Fibrosis: A Comprehensive Review |
title_sort | treatment of pulmonary disease of cystic fibrosis: a comprehensive review |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8144952/ https://www.ncbi.nlm.nih.gov/pubmed/33922413 http://dx.doi.org/10.3390/antibiotics10050486 |
work_keys_str_mv | AT gironmorenorosamaria treatmentofpulmonarydiseaseofcysticfibrosisacomprehensivereview AT garciaclementemarta treatmentofpulmonarydiseaseofcysticfibrosisacomprehensivereview AT diabcacereslayla treatmentofpulmonarydiseaseofcysticfibrosisacomprehensivereview AT martinezvergaraadrian treatmentofpulmonarydiseaseofcysticfibrosisacomprehensivereview AT martinezgarciamiguelangel treatmentofpulmonarydiseaseofcysticfibrosisacomprehensivereview AT gomezpunterrosamar treatmentofpulmonarydiseaseofcysticfibrosisacomprehensivereview |